General
Preferred name
TACRINE
Synonyms
TACRINE HYDROCHLORIDE ()
9-Amino-1,2,3,4-tetrahydroacridine hydrochloride ()
Tetrahydroaminacrine ()
Tetrahydroaminoacridine ()
Tacrine hydrochloride hydrate ()
Tacrine (hydrochloride) ()
Tacrine HCl ()
Cognex ()
Alzyme ()
NSC-72108 ()
CI-970 ()
Tacrinal ()
P&D ID
PD009117
CAS
206658-92-6
321-64-2
1684-40-8
Tags
natural product
drug
available
Approved by
FDA
First approval
1993
Drug Status
investigational
approved
withdrawn
Drug indication
Alzheimer disease
Cognition Adjuvant
Dementia Symptoms Treatment Adjunct
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Tacrine is a dual inhibitor of butyrylcholine esterase (P06276) and acetylcholinesterase (P22303). Marketed formulations may contain tacrine hydrochloride (PubChem CID 2723754).
(GtoPdb)
DESCRIPTION
Marketed formulations may contain tacrine hydrochloride (PubChem CID 2723754).
DESCRIPTION
Cholinesterase inhibitor
(Tocriscreen Total)
DESCRIPTION
Tacrine hydrochloride is a potent cholinesterase inhibitor used for the treatment of memory deficits in patients with Alzheimers's disease. Tacrine hydrochloride has been shown to inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (IC50s = 31 and 26.5 nM, respectively). Tacrine also inhibits the uptake of serotonin and norepinephrine in rat cerebral cortex and reduces depolarization-induced calcium influx through L-type calcium channels in SN56 neuronal cells.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Cholinesterase inhibitor; reported to be useful ;in the treatment of Alzheimer's disease
(LOPAC library)
DESCRIPTION
Tacrine is a centerally active acetylcholinesterase inhibitor. It has been approved for the treatment of Alzheimer's disease and other central nervous system disorders.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
6
Organisms
6
Compound Sets
35
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Ki Database
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocriscreen Total
Withdrawn 2.0
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
69
Molecular Weight
198.12
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
0
Ring Count
3
Aromatic Ring Count
2
cLogP
2.7
TPSA
38.91
Fraction CSP3
0.31
Chiral centers
0.0
Largest ring
6.0
QED
0.71
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Cholinesterase
MOA
Acetylcholinesterase inhibitor
Acetylcholinesterase Inhibitors
Butyrylcholinesterase Inhibitors
Target
Cholinesterases
ACHE & BCHE
AChR
ACHE, BCHE
Cholinesterase (ChE)
iGluR
Pathway
Neuroscience
Neuronal Signaling
Membrane Transporter/Ion Channel
Member status
member
Indication
Alzheimer's disease
ATC
N06DA01
Therapeutic Class
Parasympathomimetics
Source data
